Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDLR | P01130 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.47 |
| ▸ | PDE4A | P27815 | 7/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 4/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PDE1A | P54750 | 2/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2978657 | 0.84 | LDLR (0.74) | LDLRPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2969091 | 0.79 | ALDH1A1 (0.48) | PDE4DPDE4APDE4BPDE4CPKM | |
| SCHEMBL241870 | 0.78 | MAPK14 (0.58) | PDE4DPDE4APDE4BPDE4CPKM | |
| SCHEMBL2969098 | 0.76 | RAB9A (0.81) | RAB9A | |
| SCHEMBL2969970 | 0.73 | KDM4E (0.67) | PDE4DPKMRAB9AMAPK14 | |
| SCHEMBL2979309 | 0.73 | CA12 (0.64) | PDE4DPKMMAPK14 | |
| SCHEMBL7855514 | 0.72 | LDLR (0.60) | LDLRPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2979358 | 0.72 | LDLR (0.71) | LDLRMAPK14 | |
| SCHEMBL2974944 | 0.71 | NPC1 (0.57) | PDE4DPKMRAB9AMAPK14 | |
| SCHEMBL6782262 | 0.70 | LDLR (0.74) | LDLRMAPK14ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772432-B2 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA | 2005-02-17 | — | — | US | disclosed |
| US-6821965-B1 | IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION | ASTERZENECA AB (SE) | 2004-11-23 | — | — | US | disclosed |
| EP-1102743-B1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | disclosed |
| EP-1102743-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | IL6, IL6ST, IL2 | LDLR 3410/4885PDE4D 2839/4885PDE4A 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.